FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day 45 Mental health conditions are the leading cause of maternal mortality1 with PPD among the most [……
Read More

>> CLICK HERE << Get A FREE Copy Of My Special Report
“Can Your Retirement Survive” Today!
There's Absolutely $0 Cost To You!
We Even Pay For Shipping & Handling!
Click Here To Request Your FREE IRS Loophole Guide

This post contains affiliate links. If you use these links to buy something we may earn a commission. Thanks.”

You May Also Like